U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry ACHIRAL
Molecular Formula C22H30N6O3S
Molecular Weight 458.577
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of AVITRIPTAN

SMILES

CNS(=O)(=O)CC1=CC=C2NC=C(CCCN3CCN(CC3)C4=NC=NC=C4OC)C2=C1

InChI

InChIKey=WRZVGHXUPBWIOO-UHFFFAOYSA-N
InChI=1S/C22H30N6O3S/c1-23-32(29,30)15-17-5-6-20-19(12-17)18(13-25-20)4-3-7-27-8-10-28(11-9-27)22-21(31-2)14-24-16-26-22/h5-6,12-14,16,23,25H,3-4,7-11,15H2,1-2H3

HIDE SMILES / InChI

Molecular Formula C22H30N6O3S
Molecular Weight 458.577
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Avitriptan (BMS-180048), a new 5-HT 1B/1D receptor agonist, has been studied in phase II clinical trials in patients with migraine headaches. Later experiments have confirmed antimigraine activity together with coronary side-effect potential that is why further studies were discontinued.

Approval Year

PubMed

PubMed

TitleDatePubMed
Treatment of migraine with BMS180048: response at 2 hours. North American BMS180048 Study Group.
1996 Oct
Food-drug interactions.
2002
Triptan drugs, natural killer cell cytotoxicity, and neutrophils pro-matrix metalloproteinase-9 secretion.
2008 Nov-Dec

Sample Use Guides

Avitriptan (BMS180048) in doses of 25, 50, or 75 mg to placebo in effectiveness of treatment of a single migraine headache
Route of Administration: Oral
Substance Class Chemical
Created
by admin
on Mon Mar 31 18:23:13 GMT 2025
Edited
by admin
on Mon Mar 31 18:23:13 GMT 2025
Record UNII
6RS056L04P
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
AVITRIPTAN
INN  
INN  
Official Name English
avitriptan [INN]
Preferred Name English
1H-INDOLE-5-METHANESULFONAMIDE, 3-(3-(4-(5-METHOXY-4-PYRIMIDINYL)-1-PIPERAZINYL)PROPYL)-N-METHYL-
Systematic Name English
3-(3-(4-(5-METHOXY-4-PYRIMIDINYL)-1-PIPERAZINYL)PROPYL)-N-METHYLINDOLE-5-METHANESULFONAMIDE
Systematic Name English
Classification Tree Code System Code
NCI_THESAURUS C47794
Created by admin on Mon Mar 31 18:23:13 GMT 2025 , Edited by admin on Mon Mar 31 18:23:13 GMT 2025
NCI_THESAURUS C29710
Created by admin on Mon Mar 31 18:23:13 GMT 2025 , Edited by admin on Mon Mar 31 18:23:13 GMT 2025
Code System Code Type Description
ChEMBL
CHEMBL2110755
Created by admin on Mon Mar 31 18:23:13 GMT 2025 , Edited by admin on Mon Mar 31 18:23:13 GMT 2025
PRIMARY
SMS_ID
100000086661
Created by admin on Mon Mar 31 18:23:13 GMT 2025 , Edited by admin on Mon Mar 31 18:23:13 GMT 2025
PRIMARY
NCI_THESAURUS
C79719
Created by admin on Mon Mar 31 18:23:13 GMT 2025 , Edited by admin on Mon Mar 31 18:23:13 GMT 2025
PRIMARY
PUBCHEM
133081
Created by admin on Mon Mar 31 18:23:13 GMT 2025 , Edited by admin on Mon Mar 31 18:23:13 GMT 2025
PRIMARY
EPA CompTox
DTXSID60164718
Created by admin on Mon Mar 31 18:23:13 GMT 2025 , Edited by admin on Mon Mar 31 18:23:13 GMT 2025
PRIMARY
MESH
C103231
Created by admin on Mon Mar 31 18:23:13 GMT 2025 , Edited by admin on Mon Mar 31 18:23:13 GMT 2025
PRIMARY
INN
7561
Created by admin on Mon Mar 31 18:23:13 GMT 2025 , Edited by admin on Mon Mar 31 18:23:13 GMT 2025
PRIMARY
CAS
151140-96-4
Created by admin on Mon Mar 31 18:23:13 GMT 2025 , Edited by admin on Mon Mar 31 18:23:13 GMT 2025
PRIMARY
FDA UNII
6RS056L04P
Created by admin on Mon Mar 31 18:23:13 GMT 2025 , Edited by admin on Mon Mar 31 18:23:13 GMT 2025
PRIMARY
EVMPD
SUB05615MIG
Created by admin on Mon Mar 31 18:23:13 GMT 2025 , Edited by admin on Mon Mar 31 18:23:13 GMT 2025
PRIMARY
WIKIPEDIA
AVITRIPTAN
Created by admin on Mon Mar 31 18:23:13 GMT 2025 , Edited by admin on Mon Mar 31 18:23:13 GMT 2025
PRIMARY
Related Record Type Details
SALT/SOLVATE -> PARENT
TARGET -> AGONIST
TARGET -> AGONIST
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
The bloodto-plasma ratio PHARMACOKINETIC
Tmax PHARMACOKINETIC ORAL ADMINISTRATION

DOSE

Biological Half-life PHARMACOKINETIC DOSE

ORAL ADMINISTRATION